Related Experiment Video
Updated: Mar 9, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.5K
Physiological Study on Association between Nicotinamide N-Methyltransferase Gene Polymorphisms and Hyperlipidemia
Xiao-Juan Zhu1, Ya-Jun Lin1, Wei Chen1
1Key Lab of Training, Monitoring and Intervention of Aquatic Sports of General Administration of Sport of China, Institute of Physical Education, Jiangxi Normal University, Nanchang, China.
Biomed Research International
|December 22, 2016
Summary
A specific variation in the Nicotinamide N-methyltransferase (NNMT) gene, rs1941404, is significantly linked to hyperlipidemia. This genetic link may be explained by its effect on resting energy expenditure.
Area of Science:
- Genetics
- Metabolism
- Cardiovascular Disease
Background:
- Nicotinamide N-methyltransferase (NNMT) plays a role in energy metabolism and body mass index.
- Previous studies linked an NNMT single nucleotide polymorphism (SNP), rs694539, to cardiovascular diseases.
- The association between NNMT gene variations and hyperlipidemia remains largely unexplored.
Purpose of the Study:
- To investigate the association between NNMT gene tagSNPs and hyperlipidemia.
- To identify specific NNMT SNPs associated with hyperlipidemia.
- To explore the potential mechanisms linking NNMT polymorphism to hyperlipidemia.
Main Methods:
- Selected 19 tagSNPs in the NNMT gene using Haploview software.
- Conducted a case-control study to analyze SNP-hyperlipidemia associations.
- Employed physiological approaches to investigate underlying mechanisms.
Main Results:
- Identified a significant association between the NNMT SNP rs1941404 and hyperlipidemia.
- The rs1941404 variation's influence on resting energy expenditure is proposed as a potential mechanism.
Conclusions:
- The NNMT gene rs1941404 SNP is significantly associated with hyperlipidemia.
- Altered resting energy expenditure due to rs1941404 variation may contribute to hyperlipidemia development.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
80
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
80
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
01:27Pharmacogenetics of Drug Metabolism: Overview
77
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
77
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
52
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
52
01:29Pharmacogenomics: Identification of New Drug Targets
57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
01:27Principles of Pharmacogenetics: Types of Genetic Variants
68
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
68